Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma

Journal of Urology

Volumn 158, Issue 5, 1997, Pages 1675-1678

  Walther, Mcclellan M ^a   Yang, James C ^a   Pass, Harvey I ^a   Linehan, W Marston ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carcinoma; Interleukin 2; Metastasis; Nephrectomy; Renal cell

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR THROMBUS;

EID: 0030751476     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64091-6     Document Type: Article

References (26)

1. Middleton, R. G.: Surgery for metastatic renal cell carcinoma. J. Urol., 97: 973, 1967.
2. Johnson, D. E., Kaesler, K. E. and Samuels, M. L.: Is nephrectomy justified in patients with metastatic renal carcinoma. J. Urol., 114: 27, 1975.
3. Robertson, C. N., Linehan, W. M., Pass, H. I., Gomella, L. G., Haas, G. P., Berman, A., Merino, M. and Rosenberg, S. A.: Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J. Urol., 144: 614, 1990.
4. Walther, M. M., Alexander, R. B., Weiss, G. H., Venzon, D., Berman, A., Pass, H. I., Linehan, W. M. and Rosenberg, S. A.: Cytoreductive surgery prior to interleukin-2 based therapy in patients with metastatic renal cell carcinoma. Urology, 42: 250, 1993.
5. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S. and White, D. E.: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol., 7: 1863, 1989.
6. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Aebersold, P. M., Linehan, W. M., White, D. E. and Seipp, C. A.: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg., 210: 474, 1989.
7. Marcus, S. G., Choyke, P. L., Reiter, R., Jaffe, G. S., Alexander, R. B., Linehan, W. M., Rosenberg, S. A. and Walther, M. M.: Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J. Urol., 150: 463, 1993.
8. Bennett, R. T., Lerner, S. E., Taub, H. C., Dutcher, J. P. and Fleischmann, J.: Cytoreductive surgery for stage IV renal cell carcinoma. J. Urol., 154: 32, 1995.
9. Rackley, R., Novick, A., Klein, E., Bukowski, R., McLain, D. and Goldfarb, D.: The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J. Urol., 152: 1399, 1994.
10. Skinner, D. G., Colvin, R. B., Vermillion, C. D., Pfister, R. C. and Leadbetter, W. F.: Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer, 28: 1165, 1971.
11. Naito, S., Kimiya, K., Sakamoto, N., Soejima, T., Ueda, T., Kumazawa, J., Osada, Y., Kurozumi, T., Sagiyama, K. and Ariyoshi, A.: Prognostic factors and value of adjunctive nephrectomy in patients with stage IV renal cell carcinoma. Urology, 37: 95, 1991.
12. Fleischmann, J. D. and Kim, B.: Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J. Urol., 145: 938, 1991.
13. Belldegrun, A., Pierce, W., Kaboo, R., Tso, C.-L., Shau, H., Turcillo, P., Moldawer, N., Golub, S., deKernion, J. and Figlin, R.: Interferon-α primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-α as therapy for metastatic renal cell carcinoma. J. Urol., 150: 1384, 1993.
14. Bukowski, R. M., Goodman, P., Crawford, E. D., Sergi, J. S., Redman, B. G. and Whitehead, R. P.: Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study. J. Natl. Cancer Inst., 82: 143, 1990.
15. Thiounn, N., Mathiot, C., Dorval, T., Flam, T. A., Tartour, E., Mosseri, V., Zerbib, M., Fridman, W. H. and Debre, B.: Lack of efficacy of low-dose subcutaneous recombinant interleukin-2 and interferon-alpha in the treatment of metastatic renal cell carcinoma. Brit. J. Urol., 75: 586, 1995.
16. Bukowski, R. M., McLain, D., Olencki, T., Budd, G. T. and Murthy, S. A.: Interleukin-2: use in solid tumors. Stem Cells, 11: 26, 1993.
17. Muss, H. B.: Interferon therapy of metastatic renal cell cancer. Sem. Surg. Oncol., 4: 199, 1988.
18. Belldegrun, A., Koo, A. S., Bochner, B., Figlin, R. and deKernion, J. B.: Immunotherapy for advanced renal cell cancer: the role of radical nephrectomy. Eur. Urol., suppl. 2, 18: 42, 1990.
19. Mani, S., Todd, M. B., Katz, K. and Poo, W.-J.: Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J. Urol., 154: 35, 1995.
20. Wang, J., Walle, A., Gordon, B., Novogrodsky, A., Suthanthiran, M., Rubin, A. L., Morrison, H., Silver, R. T. and Stenzel, K. H.: Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2. Amer. J. Med., 83: 1016, 1987.
21. Spencer, W. F., Linehan, W. M., Walther, M. M., Haas, G. P., Lotze, M. T., Topalian, S. L., Yang, J. C., Merino, M. J., Lange, J. R., Pockaj, B. A. and Rosenberg, S. A.: Immunotherapy with interleukin-2 and α-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J. Urol., 147: 24, 1992.
22. Fisher, R. I., Coltman, C. A., Jr., Doroshow, J. H., Rayner, A. A., Hawkins, M. J., Mier, J. W., Wiernik, P., McMannis, J. D., Weiss, G. R. and Margolin, K. A.: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann. Intern. Med., 108: 518, 1988.
23. Buter, J., Sleijfer, D. T., van der Graaf, W. T., de Vries, E. G., Willemse, P. H. and Mulder, N. H.: A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Sem. Oncol., suppl. 9, 20: 16, 1993.
24. Sosman, J. A., Kohler, P. C., Hank, J., Moore, K. H., Bechhofer, R., Storer, B. and Sondel, P. M.: Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J. Natl. Cancer Inst., 80: 60, 1988.
25. Bukowski, R. M., Murthy, S., Sergi, J., Budd, G. T., McKeever, S., Medendorp, S. V., Tubbs, R., Gibson, V. and Finke, J.: Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alfa 2a: clinical effects. J. Biol. Response Mod., 9: 538, 1990.
26. Haas, G. P., Redman, B. G., Rao, V. K., Dybal, E., Pontes, J. E. and Hillman, G. G.: Immunotherapy for metastatic renal cell cancer: effect on the primary tumor. J. Immunother., 13: 130, 1993.